A review of the potential therapeutic role of statins in the treatment of Alzheimer’s disease: current research and opinion

References

• World Health OrganizationDementia: A Public Health PriorityGenevaWorld Health Organization2012 Available from: http://whqlibdoc.who.int/publications/2012/9789241564458_eng.pdfAccessed November 9, 2012
   Google Scholar
• Bermejo-ParejaFBenito-LéonJVegaSMedranoMJRománGCNeurological Disorders in Central Spain (NEDICES) Study GroupIncidence and subtypes of dementia in three elderly populations of central SpainJ Neurol Sci20082641–2637217727890
   PubMed Web of Science ®Google Scholar
• Bermejo-ParejaFBenito-LéonJVegaSConsistency of clinical diagnosis of dementia in NEDICES: A population-based longitudinal study in SpainJ Geriatr Psychiatry Neurol200922424625519417217
   PubMed Web of Science ®Google Scholar
• McKhannGDrachmanDFolsteinMKatzmanRPriceDStadlanEMClinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s DiseaseNeurology19843479399446610841
   PubMed Web of Science ®Google Scholar
• VillarejoABenito-LéonJTrincadoRDementia-associated mortality at thirteen years in the NEDICES Cohort StudyJ Alzheimers Dis201126354355121694455
   PubMed Web of Science ®Google Scholar
• RiveraJBermejoFFrancoMMorales-GonzálezJMBenito-LéonJUnderstanding care of people with dementia in Spain: cohabitation arrangements, rotation and rejection to long term care institutionInt J Geriatr Psychiatry200924214214818615855
   PubMed Web of Science ®Google Scholar
• AnsteyKJLipnickiDMLowLFCholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysisAm J Geriatr Psychiatry200816534335418448847
   PubMed Web of Science ®Google Scholar
• GrimmMOTschäpeJAGrimmHSZinserEGHartmannTAltered membrane fluidity and lipid raft composition in presenilin-deficient cellsActa Neurol Scand Suppl2006185S27S32
   PubMedGoogle Scholar
• LütjohannDCholesterol metabolism in the brain: importance of 24S-hydroxylationActa Neurol Scand Suppl2006185S33S42
   PubMedGoogle Scholar
• SparksDLHunsakerJC3rdScheffSWKryscioRJHensonJLMarkesberyWRCortical senile plaques in coronary artery disease, aging and Alzheimer’s diseaseNeurobiol Aging19901166016071704106
   PubMed Web of Science ®Google Scholar
• SparksDLScheffSWHunsakerJC3rdLiuHLandersTGrossDRInduction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterolExp Neurol1994126188948157129
   PubMed Web of Science ®Google Scholar
• SimonsMKellerPDe StrooperBBeyreutherKDottiCGSimonsKCholesterol depletion inhibits the generation of beta-amyloid in hippocampal neuronsProc Natl Acad Sci U S A19989511646064649600988
   PubMed Web of Science ®Google Scholar
• FassbenderKSimonsMBergmannCSimvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivoProc Natl Acad Sci U S A200198105856586111296263
   PubMed Web of Science ®Google Scholar
• SimonsKEhehaltRCholesterol, lipid rafts, and diseaseJ Clin Invest2002110559760312208858
   PubMed Web of Science ®Google Scholar
• BodovitzSKleinWLCholesterol modulates alpha-secretase cleavage of amyloid precursor proteinJ Biol Chem19962718443644408626795
   PubMed Web of Science ®Google Scholar
• RöslerMAnandRCicin-SainAEfficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trialBMJ1999318718463363810066203
   PubMed Web of Science ®Google Scholar
• PappollaMABryant-ThomasTKHerbertDMild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathologyNeurology200361219920512874399
   PubMed Web of Science ®Google Scholar
• ReissABVoloshynaIRegulation of cerebral cholesterol metabolism in Alzheimer diseaseJ Investig Med2012603576582
   PubMed Web of Science ®Google Scholar
• CorderEHSaundersAMStrittmatterWJGene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset familiesScience199326151239219238346443
   PubMed Web of Science ®Google Scholar
• SchipperHMApolipoprotein E: implications for AD neurobiology, epidemiology and risk assessmentNeurobiol Aging201132577879019482376
   PubMed Web of Science ®Google Scholar
• CreanSWardAMercaldiCJApolipoprotein E ɛ4 prevalence in Alzheimer’s disease patients varies across global populations: a systematic literature review and meta-analysisDement Geriatr Cogn Disord2011311203021124030
   PubMed Web of Science ®Google Scholar
• FarrerLACupplesLAHainesJLEffects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis ConsortiumJAMA199727816134913569343467
   PubMed Web of Science ®Google Scholar
• NuutinenTSuuronenTKauppinenASalminenAClusterin: a forgotten player in Alzheimer’s diseaseBrain Res Rev20096128910419651157
   PubMedGoogle Scholar
• HerzJChenYReelin, lipoprotein receptors and synaptic plasticityNat Rev Neurosci200671185085917053810
   PubMed Web of Science ®Google Scholar
• BjörkhemIHeverinMLeoniVMeaneySDiczfalusyUOxysterols and Alzheimer’s diseaseActa Neurol Scand Suppl2006185S43S49
   PubMedGoogle Scholar
• GhribiOPotential mechanisms linking cholesterol to Alzheimer’s disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscleJ Alzheimers Dis200815467368419096164
   PubMed Web of Science ®Google Scholar
• ShepardsonNEShankarGMSelkoeDJCholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studiesArch Neurol201168101239124421987540
   PubMedGoogle Scholar
• NotkolaILSulkavaRPekkanenJSerum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s diseaseNeuroepidemiology199817114209549720
   PubMed Web of Science ®Google Scholar
• KivipeltoMHelkalaELLaaksoMPMidlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based studyBMJ200132273001447145111408299
   PubMed Web of Science ®Google Scholar
• RomasSNTangMXBerglundLMayeuxRAPOE genotype, plasma lipids, lipoproteins, and AD in community elderlyNeurology199953351752110449113
   PubMed Web of Science ®Google Scholar
• ReitzCTangMXLuchsingerJMayeuxRRelation of plasma lipids to Alzheimer disease and vascular dementiaArch Neurol200461570571415148148
   PubMedGoogle Scholar
• MielkeMMZandiPPSjögrenMHigh total cholesterol levels in late life associated with a reduced risk of dementiaNeurology200564101689169515911792
   PubMed Web of Science ®Google Scholar
• YoshitakeTKiyoharaYKatoIIncidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama StudyNeurology1995456116111687783883
   PubMed Web of Science ®Google Scholar
• KalmijnSFoleyDWhiteLMetabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging studyArterioscler Thromb Vasc Biol200020102255226011031212
   PubMed Web of Science ®Google Scholar
• TanZSSeshadriSBeiserAPlasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham StudyArch Intern Med200316391053105712742802
   PubMedGoogle Scholar
• MartinMJHulleySBBrownerWSKullerLHWentworthDSerum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 menLancet1986285139339362877128
   PubMed Web of Science ®Google Scholar
• KlagMJFordDEMeadLASerum cholesterol in young men and subsequent cardiovascular diseaseN Engl J Med199332853133188419817
   PubMed Web of Science ®Google Scholar
• KronmalRACainKCYeZOmennGSTotal serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham dataArch Intern Med19931539106510738481074
   PubMedGoogle Scholar
• Barrett-ConnorEEdelsteinSLCorey-BloomJWiederholtWCWeight loss precedes dementia in community-dwelling older adultsJ Am Geriatr Soc19964410114711528855991
   PubMed Web of Science ®Google Scholar
• TsolakiMFountoulakisKChantziEKazisARisk factors for clinically diagnosed Alzheimer’s disease: a case-control study of a Greek populationInt Psychogeriatr1997933273419513031
   PubMedGoogle Scholar
• MorrisMCScherrPAHebertLEGlynnRJBennettDAEvansDAAssociation of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community studyArch Neurol200158101640164611594923
   PubMedGoogle Scholar
• SkoogILernfeltBLandahlS15-year longitudinal study of blood pressure and dementiaLancet19963479009114111458609748
   PubMed Web of Science ®Google Scholar
• GustafsonDRothenbergEBlennowKSteenBSkoogIAn 18-year follow-up of overweight and risk of Alzheimer diseaseArch Intern Med2003163131524152812860573
   PubMedGoogle Scholar
• LaunerLJRossGWPetrovitchHMidlife blood pressure and dementia: the Honolulu-Asia aging studyNeurobiol Aging2000211495510794848
   PubMed Web of Science ®Google Scholar
• Bermejo-ParejaFBenito-LéonJVegaQSThe NEDICES cohort of the elderly. Methodology and main neurological findingsRev Neurol2008467416423 Spanish18389461
   PubMed Web of Science ®Google Scholar
• VegaSBenito-LéonJBermejo-ParejaFSeveral factors influenced attrition in a population-based elderly cohort: neurological disorders in Central Spain StudyJ Clin Epidemiol201063221522219473811
   PubMed Web of Science ®Google Scholar
• MoralesJMBermejoFPBenito-LéonJNEDICES Study GroupMethods and demographic findings of the baseline survey of the NEDICES cohort: a door-to-door survey of neurological disorders in three communities from Central SpainPublic Health2004118642643315313596
   PubMed Web of Science ®Google Scholar
• Benito-LéonJLouisEDRivera-NavarroJMedranoMJVegaSBermejo-ParejaFLow morale is associated with increased risk of mortality in the elderly: a population-based prospective study (NEDICES)Age Ageing201039336637320299322
   PubMed Web of Science ®Google Scholar
• RefoloLMPappollaMALaFrancoisJA cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer’s diseaseNeurobiol Dis20018589089911592856
   PubMed Web of Science ®Google Scholar
• RamírezCSierraSTerceroIApoB100/LDLR−/− hypercholesterolaemic mice as a model for mild cognitive impairment and neuronal damagePLoS One201067e22712
   Web of Science ®Google Scholar
• MizunoTNakataMNaikiHCholesterol-dependent generation of a seeding amyloid beta-protein in cell cultureJ Biol Chem199927421151101511410329717
   PubMed Web of Science ®Google Scholar
• MichikawaMYanagisawaKInhibition of cholesterol production but not of nonsterol isoprenoid products induces neuronal cell deathJ Neurochem19997262278228510349836
   PubMed Web of Science ®Google Scholar
• SparksDLAlzheimer disease: statins in the treatment of Alzheimer diseaseNat Rev Neurol201171266266322009281
   PubMed Web of Science ®Google Scholar
• McGuinnessBCraigDBullockRPassmorePStatins for the prevention of dementiaCochrane Database Syst Rev2009152CD00316019370582
   PubMed Web of Science ®Google Scholar
• McGuinnessBO’HareJCraigDBullockRMaloufRPassmorePStatins for the treatment of dementiaCochrane Database Syst Rev201048CD00751420687089
   PubMed Web of Science ®Google Scholar
• WolozinBKellmanWRuosseauPCelesiaGGSiegelGDecreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitorsArch Neurol200057101439144311030795
   PubMed Web of Science ®Google Scholar
• BurgosJBenavidesJDouilletPVelascoJValdiviesoFHow statins could be evaluated successfully in clinical trials for Alzheimer’s disease?Am J Alzheimer Dis Other Demen2012273151153
   PubMed Web of Science ®Google Scholar
• LawMRWaldNJRudnickaARQuantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysisBMJ20033267404142312829554
   PubMed Web of Science ®Google Scholar
• CrisbyMThe role of pleiotropic effects of statins in dementiaActa Neurol Scand Suppl2006185S115S118
   Google Scholar
• ButterfieldDABaroneEMancusoCCholesterol-independent neuroprotective and neurotoxic activities of statins: perspectives for statin use in Alzheimer disease and other age-related neurodegenerative disordersPharmacol Res201164318018621536132
   PubMed Web of Science ®Google Scholar
• SierraSRamosMCMolinaPEsteoCVázquezJABurgosJSStatins as neuroprotectants: a comparative in vitro study of lipophilicity, blood–brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell deathJ Alzheimers Dis201123230731821098985
   PubMed Web of Science ®Google Scholar
• ShepardsonNEShankarGMSelkoeDJCholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendationsArch Neurol201168111385139222084122
   PubMedGoogle Scholar
• JickHZornbergGLJickSSSeshadriSDrachmanDAStatins and the risk of dementiaLancet200035692421627163111089820
   PubMed Web of Science ®Google Scholar
• HajjarISchumpertJHirthVWielandDEleazerGPThe impact of the use of statins on the prevalence of dementia and the progression of cognitive impairmentJ Gerontol A Biol Sci Med Sci2002577M414M41812084801
   PubMed Web of Science ®Google Scholar
• RodriguezEGDodgeHHBirzescuMAStoehrGPGanguliMUse of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological studyJ Am Geriatr Soc200250111852185612410906
   PubMed Web of Science ®Google Scholar
• YaffeKBarrett-ConnorELinFGradyDSerum lipoprotein levels, statin use, and cognitive function in older womenArch Neurol200259337838411890840
   PubMedGoogle Scholar
• ZamriniEMcGwinGRosemanJMAssociation between statin use and Alzheimer’s diseaseNeuroepidemiology2004231–2949814739574
   PubMed Web of Science ®Google Scholar
• ReaTDBreitnerJCPsatyBMStatin use and the risk of incident dementia: the Cardiovascular Health StudyArch Neurol20056271047105116009757
   PubMed Web of Science ®Google Scholar
• DufouilCRichardFFiévetNAPOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City StudyNeurology20056491531153815883313
   PubMed Web of Science ®Google Scholar
• CramerCHaanMNGaleaSLangaKMKalbfleischJDUse of statins and incidence of dementia and cognitive impairment without dementia in a cohort studyNeurology200871534435018663180
   PubMed Web of Science ®Google Scholar
• HaagMDHofmanAKoudstaalPJStrickerBHBretelerMMStatins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam StudyJ Neurol Neurosurg Psychiatry2009801131718931004
   PubMed Web of Science ®Google Scholar
• ZandiPPSparksDLKhachaturianASCache County Study InvestigatorsDo statins reduce risk of incident dementia and Alzheimer disease? The Cache County StudyArch Gen Psychiatry200562221722415699299
   PubMed Web of Science ®Google Scholar
• ArvanitakisZSchneiderJAWilsonRSStatins, incident Alzheimer disease, change in cognitive function, and neuropathologyNeurology20087019 Pt 21795180218199831
   PubMed Web of Science ®Google Scholar
• Benito-LéonJLouisEDVegaSBermejo-ParejaFStatins and cognitive functioning in the elderly: a population-based studyJ Alzheimers Dis20102119510220413854
   PubMed Web of Science ®Google Scholar
• TrompetSvan VlietPde CraenAJPravastatin and cognitive function in the elderly. Results of the PROSPER studyJ Neurol20102571859019653027
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet2002360932672212114036
   PubMed Web of Science ®Google Scholar
• HarrisonRWAshtonCHDo cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteersBr J Clin Pharmacol19943732312368198930
   PubMed Web of Science ®Google Scholar
• KostisJBRosenRCWilsonACCentral nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemiaJ Clin Pharmacol199434109899967836550
   PubMed Web of Science ®Google Scholar
• CutlerNSramekJVeroffABlockGStaufferLLinesCEffects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemiaBr J Clin Pharmacol19953933333367619678
   PubMed Web of Science ®Google Scholar
• GengoFCwudzinskiDKinkelPBlockGStaufferLLinesCEffects of treatment with lovastatin and pravastatin on daytime cognitive performanceClin Cardiol19951842092147788948
   PubMed Web of Science ®Google Scholar
• GibellatoMGMooreJLSelbyKBowerEAEffects of lovastatin and pravastatin on cognitive function in military aircrewAviat Space Environ Med200172980581211565814
   PubMedGoogle Scholar
• GolombBACriquiMHWhiteHLDimsdaleJEThe UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected noncardiac outcomesControl Clin Trials200425217820215020036
   PubMedGoogle Scholar
• SummersMJOliverKRCoombesJSFassettRGEffect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trialPharmacotherapy200727218319017253908
   PubMed Web of Science ®Google Scholar
• SparksDLKryscioRJConnorDJCholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohortNeurodegener Dis201071–318318620224282
   PubMed Web of Science ®Google Scholar
• SparksDLKryscioRJSabbaghMNConnorDJSparksLMLiebsackCReduced risk of incident AD with elective statin use in a clinical trial cohortCurr Alzheimer Res20085441642118690839
   PubMed Web of Science ®Google Scholar
• CarlssonCMGleasonCEHessTMEffects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer’s diseaseJ Alzheimers Dis200813218719718376061
   PubMed Web of Science ®Google Scholar
• SantanelloNCBarberBLApplegateWBEffect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot StudyJ Am Geriatr Soc19974518148994481
   PubMed Web of Science ®Google Scholar
• MuldoonMFBargerSDRyanCMEffects of lovastatin on cognitive function and psychological well-beingAm J Med2000108753854610806282
   PubMed Web of Science ®Google Scholar
• MuldoonMFRyanCMSereikaSMFloryJDManuckSBRandomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adultsAm J Med20041171182382915589485
   PubMed Web of Science ®Google Scholar
• Berk-PlankenIde KonigIStolkRJansenHHoogerbruggeNAtorvastatin, diabetic dyslipidemia, and cognitive functioningDiabetes Care20022571250125112087035
   PubMed Web of Science ®Google Scholar
• ParaleGPBahetiNNKulkarniPMPanchalNVEffects of atorvastatin on higher functionsEur J Clin Pharmacol200662425926516489473
   PubMed Web of Science ®Google Scholar
• Diabetes Atorvastin Lipid Intervention (DALI) Study GroupThe effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemiaDiabetes Care20012481335134111473066
   PubMed Web of Science ®Google Scholar
• SimonsMSchwärzlerFLütjohannDTreatment with simvastatin in normocholesterolemic patients with Alzheimer’s disease: A 26-week randomized, placebo-controlled, double-blind trialAnn Neurol200252334635012205648
   PubMed Web of Science ®Google Scholar
• FeldmanHHDoodyRSKivipeltoMLEADe InvestigatorsRandomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADeNeurology2010741295696420200346
   PubMed Web of Science ®Google Scholar
• SanoMBellKLGalaskoDA randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer diseaseNeurology201177655656321795660
   PubMed Web of Science ®Google Scholar
• SparksDLConnorDJSabbaghMNPetersenRBLopezJBrownePCirculating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer’s disease: results of the Alzheimer’s Disease Cholesterol-Lowering Treatment (ADCLT) trialActa Neurol Scand Suppl2006185S3S7
   PubMedGoogle Scholar
• SparksDLSabbaghMNConnorDJAtorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary resultsArch Neurol200562575375715883262
   PubMedGoogle Scholar
• RockwoodKKirklandSHoganDBUse of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly peopleArch Neurol200259222322711843693
   PubMed Web of Science ®Google Scholar
• RedelmeierDAThiruchelvamDDanemanNDelirium after elective surgery among elderly patients taking statinsCMAJ2008179764565218809895
   PubMed Web of Science ®Google Scholar
• EvansMAGolombBAStatin-associated adverse cognitive effects: survey results from 171 patientsPharmacotherapy200929780081119558254
   PubMed Web of Science ®Google Scholar
• AgostiniJVTinettiMEHanLMcAvayGFoodyJMConcatoJEffects of statin use on muscle strength, cognition, and depressive symptoms in older adultsJ Am Geriatr Soc200755342042517341246
   PubMed Web of Science ®Google Scholar
• GlasserSPWadleyVJuddSThe association of statin use and statin type and cognitive performance: analysis of the reasons for geographic and racial differences in stroke (REGARDS) studyClin Cardiol201033528028820513066
   PubMed Web of Science ®Google Scholar
• Rojas-FernandezCHCameronJCIs statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendationsAnn Pharmacother201246454955722474137
   PubMed Web of Science ®Google Scholar
• JukemaJWCannonCPde CraenAJWestendorpRGTrompetSThe controversies of statin therapy: weighing the evidenceJ Am Coll Cardiol2012601087588122902202
   PubMed Web of Science ®Google Scholar
• Institute for the Study of Aging (ISOA)Lipitor as a treatment for Alzheimer’s diseaseClinical Trials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2001 [updated November 8, 2006]. Available from: http://clinicaltrials.gov/ct2/show/NCT00024531. NLM identifier: NCT00024531Accessed September 30, 2012
   Google Scholar
• PfizerTo evaluate the safety and effectiveness of atorvastatin plus a cholinesterase inhibitor in AD patientsClinical Trialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2005 [updated July 9, 2008]. Available from: http://clinicaltrials.gov/ct2/show/NCT00151502. NLM identifier: NCT00151502Accessed September 30, 2012
   Google Scholar
• National Institute on Aging (NIA)Cholesterol lowering agent to slow progression (CLASP) of Alzheimer’s disease studyClinical Trials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2003 [updated July 24, 2009]. Available from: http://clinicaltrials.nlm.nih.gov/ct2/show/NCT00053599. NLM identifier: NCT00053599Accessed September 30, 2012
   Google Scholar